EXHIBIT 10.44

 

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4)

and 240.24b-2.

 

FIRST AMENDMENT
TO THE
COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT

 

THIS FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH, DEVELOPMENT,
COMMERCIALIZATION AND LICENSE AGREEMENT (the “First Amendment”) is made by and
between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal
place of business at 4767 Nexus Centre Drive, San Diego, CA 92121, and FIRMENICH
SA, a Swiss Company, having its principal place of business at 1, route des
Jeunes,1211 Geneva 8, Switzerland (“Firmenich”).

 

WHEREAS, Senomyx and Firmenich entered into that certain Collaborative Research,
Development, Commercialization and License Agreement dated as of July 28, 2009
(the “Agreement”); and

 

WHEREAS, the parties wish to amend the Agreement in the manner set forth in this
First Amendment (capitalized terms used but not otherwise defined in this First
Amendment shall have the meanings given such terms in the Agreement).

 

NOW, THEREFORE, in consideration of the foregoing premises and of the covenants,
representations and agreements set forth below, the parties hereby agree to
amend the Agreement as follows:

 

AGREEMENT

 

1.                                        The parties acknowledge and agree that
for purposes of the Agreement, the “first Regulatory Approval of S6973 in the
United State” has been achieved.

 

2.                                        The parties further acknowledge and
agree that wherever the phrase “first Regulatory Approval” is used anywhere in
the Agreement with respect to any specific country or geography, that
notwithstanding anything to the contrary in the Agreement such “first Regulatory
Approval” will be deemed to occur when […***…].

 

3.                                        In consideration for a non-refundable
and non-creditable payment by Firmenich to Senomyx of US $2,000,000, which
amount shall be paid by not later than November 13, 2009, the parties agree
that:

 

(a)                                  The payment amount set forth in
Section 7.1.1(b) of the Agreement shall hereafter be US$8,000,000 instead of
US$10,000,000.

 

(b)                                  The reference to […***…] in Section 7.1.2.1
of the Agreement shall hereafter refer to February 1, 2010; and

 

--------------------------------------------------------------------------------

***Confidential Treatment Requested

 

1

--------------------------------------------------------------------------------

 

(c)                                  Notwithstanding anything to the contrary in
the Agreement, Firmenich’s right to select S6973 for development under the
Collaborative Program pursuant to Section 3.1.4 shall expire as of February 1,
2010, subject to the earlier termination of the Agreement, and following such
date Firmenich shall have no remaining right to select S6973 for development
under the Agreement.

 

4.                                        The parties acknowledge and agree that
Senomyx may disclose the material financial and business terms of this Amendment
as contemplated by Section 10.5 of the Agreement. The parties further
acknowledge and agree that Senomyx may issue a press release to announce the
execution of this Amendment and its material terms, including the nature of the
modifications to the Agreement and the amount, timing and other terms of the
payments contemplated by this Amendment. […***…] Notwithstanding the foregoing,
the content of the press release shall not […***…].

 

5.                                        Except as specifically amended by this
First Amendment, the terms and conditions of the Agreement shall remain in full
force and effect.

 

6.                                        This First Amendment will be governed
by the laws of the State of […***…], as such laws are applied to contracts
entered into and to be performed entirely within such State.

 

7.                                        This First Amendment may be executed
in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

--------------------------------------------------------------------------------

***Confidential Treatment Requested

 

2

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this First Amendment effective as
of the date of the last signature set forth below.

 

FIRMENICH SA

 

FIRMENICH SA

 

 

 

 

 

 

By:

 

 

By:

 

 

 

 

 

 

 

 

 

 

 

Title:

 

 

Title:

 

 

 

 

 

 

 

 

 

 

 

Date:

 

 

Date:

 

 

 

SENOMYX, INC.

 

 

By:

/s/ Kent Snyder

 

 

Kent Snyder

 

 

 

 

Title:

CEO and Chairman

 

 

 

 

 

 

 

Date:

October 30, 2009

 

 

 

[SIGNATURE PAGE TO FIRST AMENDMENT]

 

3

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties have executed this First Amendment effective as
of the date of the last signature set forth below.

 

FIRMENICH SA

 

FIRMENICH SA

 

 

 

 

 

 

By:

/s/ Donald Hartman

 

By:

/s/ Friedrich Busse

 

 

 

 

 

 

 

 

 

 

Title:

Corp. VP Flavors

 

Title:

Corp. VP Strategic Development

 

 

 

 

 

 

 

 

 

 

Date:

30 Oct. 2009

 

Date:

30 Octobre 2009

 

 

SENOMYX, INC.

 

 

By:

 

 

 

Kent Snyder

 

 

 

 

Title:

CEO and Chairman

 

 

 

 

 

 

 

Date:

 

 

 

 

[SIGNATURE PAGE TO FIRST AMENDMENT]

 

3

--------------------------------------------------------------------------------